Article
Geriatrics & Gerontology
Esther S. Oh, Paul B. Rosenberg, Gail B. Rattinger, Elizabeth A. Stuart, Constantine G. Lyketsos, Jeannie-Marie S. Leoutsakos
Summary: This study found that the use of atypical antipsychotics in AD patients was associated with worse cognition and function, while the use of non-SSRI antidepressants was associated with better function. However, no drug class was associated with improvement in neuropsychiatric symptoms.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2021)
Article
Neurosciences
Deidiane Elisa Ribeiro, Lyvia Lintzmaier Petiz, Talita Glaser, Agatha Oliveira-Giacomelli, Roberta Andrejew, Fernando de Azevedo Ribeiro Saab, Milena da Silva Milanis, Henrique Correia Campos, Vanessa Fernandes Arnaud Sampaio, Sophia La Banca, Beatriz Monteiro Longo, Claudiana Lameu, Yong Tang, Rodrigo Ribeiro Resende, Sergio T. Ferreira, Henning Ulrich
Summary: About 10 million new cases of dementia occur globally each year, with up to 70% attributed to Alzheimer's disease (AD). AD patients often experience non-cognitive symptoms known as behavioral and psychological symptoms of dementia (BPSDs), including sleep disorders and mood alterations such as depression and apathy. BPSDs have a significant impact on AD patients, caregivers, public health systems, and the economy. Understanding the role of purinergic signaling, particularly the A1, A2A, and P2X7 receptors, in AD may provide new therapeutic approaches for the disease and related conditions.
Article
Neurosciences
Detao Meng, Zhaohui Jin, Yixuan Wang, Boyan Fang
Summary: The study aimed to investigate the effect of neuropsychiatric symptoms on cognitive decline in patients with Parkinson's disease. Longitudinal data from the Parkinson's Progression Markers Initiative cohort were analyzed using linear mixed-effects models and generalized estimating equations. The results showed that depression, anxiety, apathy, and psychosis were associated with global cognitive decline, and patients with these symptoms were more likely to meet the criteria for mild cognitive impairment.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Pharmacology & Pharmacy
Metin Yesiltepe, Bariscan Cimen, Yildirim Sara
Summary: Alzheimer's Disease (AD) is the leading cause of dementia and there is currently no effective treatment for the neuropsychiatric symptoms (NPS) in AD patients. However, this study found that chronic vagal nerve stimulation (VNS) can effectively treat NPS in an AD rat model, particularly depression and anxiety, without impairing cognition.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Clinical Neurology
Weibing Liu, Tatsuya Yamamoto, Yoshitaka Yamanaka, Masato Asahina, Tomoyuki Uchiyama, Shigeki Hirano, Keisuke Shimizu, Yoshinori Higuchi, Satoshi Kuwabara
Summary: Frontal lobe functions, depression, and verbal fluency significantly worsened 3 years after STN-DBS. The UPDRS part I score and higher impulsivity might be associated with QOL after STN-DBS.
FRONTIERS IN NEUROLOGY
(2021)
Editorial Material
Clinical Neurology
Byron Creese, Katie Lannon
Summary: New research based on genome-wide association studies in Alzheimer's disease has identified molecular mechanisms that are also seen in some psychiatric disorders. The study used omics data and has the potential to reveal unknown disease mechanisms. However, insufficient information about neuropsychiatric symptoms in Alzheimer's disease patients limits the conclusions.
NATURE REVIEWS NEUROLOGY
(2022)
Article
Clinical Neurology
Hanna Cho, Nidhi S. Mundada, Liana G. Apostolova, Maria C. Carrillo, Ranjani Shankar, Alinda N. Amuiri, Ehud Zeltzer, Charles C. Windon, David N. Soleimani-Meigooni, Jeremy A. Tanner, Courtney Lawhn Heath, Orit H. Lesman-Segev, Paul Aisen, Ani Eloyan, Hye Sun Lee, Dustin B. Hammers, Kala Kirby, Jeffrey L. Dage, Anne Fagan, Tatiana Foroud, Lea T. Grinberg, Clifford R. Jack, Joel Kramer, Walter A. Kukull, Melissa E. Murray, Kelly Nudelman, Arthur Toga, Prashanthi Vemuri, Alireza Atri, Gregory S. Day, Ranjan Duara, Neill R. Graff-Radford, Lawrence S. Honig, David T. Jones, Joseph Masdeu, Mario Mendez, Erik Musiek, Chiadi U. Onyike, Meghan Riddle, Emily J. Rogalski, Stephen Salloway, Sharon Sha, Raymond Scott Turner, Thomas S. Wingo, David A. Wolk, Robert Koeppe, Leonardo Iaccarino, Bradford C. Dickerson, Renaud La Joie, Gil D. Rabinovici
Summary: This study describes the baseline amyloid-beta and tau-PET results in early-onset Alzheimer's disease. The results show that amyloid-PET can help distinguish early-onset Alzheimer's disease from other cognitive impairments, and tau-PET signal is elevated in a parietal-predominant pattern with higher burden in younger female patients.
ALZHEIMERS & DEMENTIA
(2023)
Article
Dermatology
Maryanne Senna, Justin Ko, Marc Glashofer, Chloe Walker, Susan Ball, Emily Edson-Heredia, Baojin Zhu, Jerry Shapiro
Summary: Although the severity of alopecia areata (AA) is often determined by the extent of scalp hair loss, its impact on quality of life (QOL) can also be a defining factor. This study found that patients' perception of disease severity, as well as eyelash and eyebrow involvement, were significant predictors of diminished QOL.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Clinical Neurology
Lucy L. Gibson, Lea T. Grinberg, Dominic Ffytche, Renata E. P. Leite, Roberta D. Rodriguez, Renata E. L. Ferretti-Rebustini, Carlos A. Pasqualucci, Ricardo Nitrini, Wilson Jacob-Filho, Dag Aarsland, Claudia K. Suemoto
Summary: In a post mortem study on LBD, hallucinations were found to be associated with higher LB Braak stages, while higher NFT Braak staging was associated with depression, agitation, and greater number of symptoms. Patients with dual AD+LBD pathology had the highest risk of hallucinations, agitation, apathy, and total symptoms.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Anders Gustavsson, Lars Lau Raket, Mathias Lilja, Loes Rutten-Jacobs, Hanna Fues Wahl, Marloes Bagijn, Erik Stomrud, Oskar Hansson, Sebastian Palmqvist
Summary: The study found that participants with prodromal AD (A beta-positive MCI) reported better health utility, while health utility in preclinical AD (A beta-positive CU) was similar to controls in the Swedish BioFINDER study.
ALZHEIMERS & DEMENTIA
(2021)
Article
Clinical Neurology
Angelina J. Polsinelli, Ryan J. Wonderlin, Dustin B. Hammers, Alex Pena Garcia, Ani Eloyan, Alexander Taurone, Maryanne Thangarajah, Laurel Beckett, Sujuan Gao, Sophia Wang, Kala Kirby, Paige E. Logan, Paul Aisen, Jeffrey L. Dage, Tatiana Foroud, Percy Griffin, Leonardo Iaccarino, Joel H. Kramer, Robert Koeppe, Walter A. Kukull, Renaud La Joie, Nidhi S. Mundada, Melissa E. Murray, Kelly Nudelman, David N. Soleimani-Meigooni, Malia Rumbaugh, Arthur W. Toga, Alexandra Touroutoglou, Prashanthi Vemuri, Alireza Atri, Gregory S. Day, Ranjan Duara, Neill R. Graff-Radford, Lawrence S. Honig, David T. Jones, Joseph Masdeu, Mario F. Mendez, Kyle Womack, Erik Musiek, Chiadi U. Onyike, Meghan Riddle, Emily Rogalski, Steven Salloway, Sharon J. Sha, Raymond S. Turner, Thomas S. Wingo, David A. Wolk, Maria C. Carrillo, Bradford C. Dickerson, Gil D. Rabinovici, Liana G. Apostolova
Summary: We investigated NPS and psychotropic medication use in individuals with EOAD using data from LEADS. Affective behaviors were most common in EOAD, while tension and impulse control behaviors were more common in EOnonAD. Psychotropic medication use was higher in EOnonAD. Overall, NPS burden and psychotropic medication use were higher in EOnonAD compared to EOAD participants.
ALZHEIMERS & DEMENTIA
(2023)
Article
Multidisciplinary Sciences
Shengfang Song, Zhehui Luo, Chenxi Li, Xuemei Huang, Eric J. Shiroma, Eleanor M. Simonsick, Honglei Chen
Summary: This study longitudinally assessed depressive symptoms in older adults with Parkinson's disease (PD) and found that depressive symptoms start to increase a few years prior to PD diagnosis and become significantly different from expected levels one year before diagnosis.
Review
Cell Biology
Michelle Zonkowski Ribas, Gabriela Ferreira Paticcie, Felipe Micelli Noleto, Luis Guilherme Ramanzini, Arthur de Oliveira Veras, Renato Dall'Oglio, Luciano Barroso de Albuquerque Filho, Jaiurte Gomes Martins da Silva, Micael Porto Portela Lima, Beatriz Esmeraldo Teixeira, Gabrielle Nunes de Sousa, Andre Felipe Costa Alves, Lara Maria Fujita Vieira Lima, Camilla Costa Sallem, Tulia Fernanda Meira Garcia, Isadora Monica Ponte de Oliveirac, Raul Sancho de Carvalho Rocha, Mikaio de Sousa Juca, Sarah Tavora Barroso, Julio Cesar Claudino dos Santos
Summary: Alzheimer's disease (AD) is a common form of dementia, which leads to various consequences in the patient's life. Dysexecutive syndrome (DS), the second most frequent neuropsychological dysfunction in AD, affects multiple brain areas and causes cognitive, behavioral, and emotional difficulties. Further research is needed to analyze the association between DS and AD and identify potential evidence gaps.
AGEING RESEARCH REVIEWS
(2023)
Article
Neurosciences
Qiao-Ling Cao, Yan Sun, Hao Hu, Zuo-teng Wang, Lan Tan, Jin-Tai Yu
Summary: The burden of cerebral small vessel disease (CSVD) is associated with neuropsychiatric symptoms (NPS) in elderly individuals without dementia. Different markers of CSVD are associated with specific subsyndromes of NPS, indicating regional differences in CSVD occurrence.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Medicine, General & Internal
Laia Montoliu-Gaya, Daniel Alcolea, Nicholas J. Ashton, Jordi Pegueroles, Johannes Levin, Beatriz Bosch, Juan Lantero-Rodriguez, Maria Carmona-Iragui, Olivia Wagemann, Mircea Balasa, Przemyslaw Radoslaw Kac, Isabel Barroeta, Albert Llado, Wagner S. Brum, Laura Videla, Fernando Gonzalez-Ortiz, Bessy Benejam, Javier Jose Arranz Martinez, Thomas K. Karikari, Georg Nuebling, Alexandre Bejanin, Andrea L. Benedet, Rafael Blesa, Alberto Lleo, Kaj Blennow, Raquel Sanchez-Valle, Henrik Zetterberg, Juan Fortea
Summary: This study found that plasma GFAP levels are associated with the diagnosis and progression of Alzheimer's disease in adults with Down syndrome, indicating its potential as a biomarker. This biomarker may have applications in clinical practice and clinical trials.
Letter
Psychology, Clinical
Yan Luo, Toshi A. Furukawa
PSYCHOLOGICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Yusuke Tsutsumi, Yasushi Tsujimoto, Aran Tajika, Kenji Omae, Tomoko Fujii, Akira Onishi, Yuki Kataoka, Morihiro Katsura, Hisashi Noma, Ethan Sahker, Edoardo Giuseppe Ostinelli, Toshi A. Furukawa
Summary: The study examines the magnitude and variability of contextual effects (PCE) in placebo-controlled trials across various interventions. The results show that subjective outcomes are influenced more by specific intervention effects compared to objective or semiobjective outcomes. The study highlights the importance of considering each PCE individually in different clinical settings.
BMJ EVIDENCE-BASED MEDICINE
(2023)
Article
Oncology
Tatsuo Akechi, Takuhiro Yamaguchi, Megumi Uchida, Fuminobu Imai, Kanae Momino, Fujika Katsuki, Naomi Sakurai, Tempei Miyaji, Tomoe Mashiko, Masaru Horikoshi, Toshi A. Furukawa, Akiyo Yoshimura, Shinji Ohno, Natsue Uehiro, Kenji Higaki, Yoshie Hasegawa, Kazuhisa Akahane, Yosuke Uchitomi, Hiroji Iwata
Summary: This study investigated the effectiveness of smartphone problem-solving therapy and behavioral activation applications in breast cancer survivors. The results showed that smartphone psychotherapy offers a promising way to reduce fear of cancer recurrence in this population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Clinical Neurology
Rie Toyomoto, Masatsugu Sakata, Kazufumi Yoshida, Yan Luo, Yukako Nakagami, Teruhisa Uwatoko, Tomonari Shimamoto, Ethan Sahker, Aran Tajika, Hidemichi Suga, Hiroshi Ito, Michihisa Sumi, Takashi Muto, Masataka Itoi, Hiroshi Ichikawaj, Masaya Ikegawaj, Nao Shiraishi, Takafumi Watanabe, Edward R. Watkins, Hisashi Noma, Masaru Horikoshi, Taku Iwami, Toshi A. Furukawa
Summary: This study explored the prognostic factors and effect modifiers for five common components of internet-cognitive behavioural therapy (iCBT) for depression. The study found that baseline depressive symptoms and exercise habits are factors influencing the effectiveness of the self-monitoring component.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Letter
Health Care Sciences & Services
Yuki Kataoka, Masahiro Banno, Yasushi Tsujimoto, Toshi A. Furukawa
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2023)
Article
Mathematical & Computational Biology
Orestis Efthimiou, Jeroen Hoogland, Thomas P. A. Debray, Michael Seo, Toshiaki A. Furukawa, Matthias Egger, Ian R. White
Summary: When individual patient data from a randomized trial are available, statistical and machine learning methods can be used to develop models for predicting treatment effects and guide personalized treatment choices. This article proposes measures to evaluate personalized treatment effect predictions, including discrimination and calibration. The methods are applicable to different outcome types and prediction models.
STATISTICS IN MEDICINE
(2023)
Article
Mathematical & Computational Biology
Tasnim Hamza, Konstantina Chalkou, Fabio Pellegrini, Jens Kuhle, Pascal Benkert, Johannes Lorscheider, Chiara Zecca, Cynthia P. Iglesias-Urrutia, Andrea Manca, Toshi A. Furukawa, Andrea Cipriani, Georgia Salanti
Summary: In network meta-analysis (NMA), all relevant evidence about health outcomes with competing treatments is synthesized. The evidence can come from randomized clinical trials (RCT) or non-randomized studies (NRS) as individual participant data (IPD) or aggregate data (AD). A suite of Bayesian NMA and network meta-regression (NMR) models are introduced to allow for cross-design and cross-format synthesis. The models integrate a three-level hierarchical model for synthesizing IPD and AD into four approaches, accounting for differences in design and risk of bias (RoB) in the evidence.
RESEARCH SYNTHESIS METHODS
(2023)
Article
Health Care Sciences & Services
Yuting Wang, Tahir Devji, Alonso Carrasco-Labra, Anila Qasim, Qiukui Hao, Elena Kum, Niveditha Devasenapathy, Madeleine T. King, Berend Terluin, Caroline B. Terwee, Michae Walsh, Toshi A. Furukawa, Yasushi Tsujimoto, Gordon H. Guyatt
Summary: The minimal important difference (MID) is the smallest change or difference that patients perceive as important to interpret patient-reported outcome measure (PROM) scores. A credibility instrument for anchor-based MID assessment typically includes a core item evaluating the correlation between the PROM and the anchor. However, many MID studies do not report this correlation. To address this, we developed an alternative construct proximity item to assess credibility when the correlation is lacking.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2023)
Article
Health Care Sciences & Services
Tomotsugu Seki, Morio Aki, Toshi A. Furukawa, Hirotsugu Kawashima, Tomotaka Miki, Yujin Sawaki, Takaaki Ando, Kentaro Katsuragi, Takahiko Kawashima, Senkei Ueno, Takashi Miyagi, Shun'ichi Noma, Shiro Tanaka, Koji Kawakami
Summary: This study aimed to examine whether an electronic health record (EHR)-nested reminder system can help patients achieve therapeutically appropriate serum lithium levels. The study found insufficient evidence for the reminder system to increase the achievement of therapeutic serum lithium concentrations, but it did increase the number of monitoring. The EHR-based reminders may be useful for improving the quality of care for patients on lithium maintenance therapy.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2023)
Review
Medicine, General & Internal
Yuki Furukawa, Yan Luo, Satoshi Funada, Akira Onishi, Edoardo Ostinelli, Tasnim Hamza, Toshi A. Furukawa, Yuki Kataoka
Summary: This study aimed to identify the optimal treatment duration with antibiotics for adults with community-acquired pneumonia (CAP) through a systematic review and duration-effect meta-analysis. The findings suggest that a shorter treatment duration (3-5 days) may provide the best balance between efficacy and treatment burden for treating CAP in adults who have achieved clinical stability. However, the limited number of included studies and the overall moderate-to-high risk of bias may affect the certainty of the results, highlighting the need for further research.
Article
Medicine, General & Internal
Toshi A. Furukawa, Aran Tajika, Masatsugu Sakata, Yan Luo, Rie Toyomoto, Masaru Horikoshi, Tatsuo Akechi, Norito Kawakami, Takeo Nakayama, Naoki Kondo, Shingo Fukuma, Hisashi Noma, Helen Christensen, Ronald C. Kessler, Pim Cuijpers, James M. S. Wason
Summary: This study aims to develop an iCBT platform that can adapt to the evolving internet technologies and examine the short-term and long-term efficacy of different CBT skills for depression. The study will recruit 3520 participants with subthreshold depression and approximately 1700 participants without subthreshold depression to evaluate the short-term efficacy for reducing depressive symptoms and the long-term efficacy for preventing depression in the total sample.
Article
Psychology, Clinical
Toshi A. Furukawa, Susumu Iwata, Masaru Horikoshi, Masatsugu Sakata, Rie Toyomoto, Yan Luo, Aran Tajika, Noriko Kudo, Eiji Aramaki
Summary: This study investigated the potential use of artificial intelligence and natural language processing to facilitate cognitive restructuring in internet cognitive-behavior therapy. The language model T5 was used to predict thoughts and feelings, and the accuracy of the predictions was validated. The results showed that correctly predicted thought-feeling pairs led to more effective reduction of negative emotions in cognitive restructuring.
COGNITIVE THERAPY AND RESEARCH
(2023)
Article
Medicine, General & Internal
Adriani Nikolakopoulou, Anna Chaimani, Toshi A. Furukawa, Theodoros Papakonstantinou, Gerta Ruecker, Guido Schwarzer
Summary: The placebo effect is the result of a participant's belief or expectation in the effectiveness of a treatment. It can play a significant role in certain conditions, particularly those with subjective symptoms. Factors such as informed consent, number of arms in a study, occurrence of adverse events, and quality of blinding can influence placebo response and introduce bias in randomized controlled trials.
BMJ EVIDENCE-BASED MEDICINE
(2023)
Article
Psychiatry
Andrea Cipriani, Soraya Seedat, Lea Milligan, Georgia Salanti, Malcolm Macleod, Janna Hastings, James Thomas, Susan Michie, Toshi A. Furukawa, David Gilbert, Karla Soares-Weiser, Carmen Moreno, Stefan Leucht, Matthias Egger, Parisa Mansoori, James M. Barker, Spyridon Siafis, Edoardo Giuseppe Ostinelli, Robert McCutcheon, Simonne Wright, Matilda Simpson, Olufisayo Elugbadebo, Virginia Chiocchia, Thomy Tonia, Rania Elgarf, Ayse Kurtulmus, Emily Sena, Ouma Simple, Niall Boyce, Sophie Chung, Anjuli Sharma, Miranda Wolpert, Jennifer Potts, Julian H. Elliott
Summary: Progress in developing novel therapies for anxiety, depression, and psychosis has been slow, and predicting effective treatments for individuals remains challenging. Understanding the mechanisms of mental health conditions, developing targeted interventions, and improving diagnosis and prediction are crucial. Living systematic reviews can enhance efficiency and reduce waste in research. The Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis (GALENOS) aims to catalog and evaluate relevant scientific research, involving both human and preclinical studies, to advance mental health science. GALENOS will also facilitate collaboration and identify key research questions, accelerating the translation of discovery science into effective interventions.
Article
Psychology, Clinical
Ryuhei So, Naoki Emura, Kozue Okazaki, Sakiko Takeda, Takashi Sunami, Kohei Kitagawa, Yoshitake Takebayashi, Toshi A. Furukawa
Summary: This study compared the effects of therapist-guided internet interventions with unguided ones on gambling behavior, cognition, and stage of change. The results showed that there were no significant differences between the guided and unguided groups in terms of improvement in gambling symptoms, behavior, and stage of change.
ADDICTIVE BEHAVIORS
(2024)
